NYU's star rheumatologist, Dr. Jose Scher, wit on the fly at #EULAR2023 https://t.co/O9afiVHSV5

Can combined US examination of nail-enthesis complex & nailfold videocapillaroscopy differentiate PsA from PSO RA and HC? Brief answer is no, but: -PsA > tortuous capillaries vs. PSO & HC -Abnormalities in PSO to be used as predictor of PsA? TBC... @RheumNow #EULAR23 POS0025 https://t.co/RNbpht8QGh

#EULAR2023 #POS1147 Primary endpoint for Cenerimod (S1P1 modulator) phase 2 RCT in #SLE was not met after multiple testing. Post-hoc analysis showed greater reduction in SRI-4 and mSLEDAI in IFN-High vs IFN-Low at 6mths. A biomarker to stratify response in Phase 3 @RheumNow https://t.co/wKM5V1JgXT

Fluorescence optical imaging in early arthritis? Nice images but not ready for clinics yet Can not differentiate OA from RA & PsA SLE/SSc associated arthritis display a specific pattern, but usually auto-antibody profiles help w/ diagnosis OP0173 #EULAR23 @Rheunow https://t.co/bAMi9kDKS5

JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023

Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0

Professor Ingrid Lundberg reviews the co associations amongst the inflammatory myopathies #EULAR2023 https://t.co/B9Idyz90Lh

🛑Doing Hands and feet Xray in undifferentiated arthritis? Retro study 700+pts shows: ✔️only few patients w/ UA present w/ RA-associated erosions at presentation ✔️Rarely leads to change in diagnosis or prognosis. Will you stop? I probably won't 👀 @RheumNow #EULAR23 OP0172 https://t.co/BRpmDqaN0r

#Lupus #nephritis - many trials and this is one company #Roche and other #pharmaceutical CO’s are also involved #Hope #SLE #EULAR2023 ⁦@RheumNow⁩ ⁦@eular_org⁩ https://t.co/Giu2iUqq6j

The steroid dosing in SAPHYR (sarilumab in PMR): Bottom two trajectories: sarilumab protocol & actual Top two trajectories: placebo protocol & actual Fascinating that with sarilumab, more PNL only really in play at PNL <3mg/d. Def takes the heat out POS0715 #EULAR2023 @RheumNow https://t.co/aEC8cQaR7O

RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its Faculty.

• Erdheim-Chester disease (ECD) is associated with Langerhans cell histiocytosis (LCH) • Bone pain, xanthelasma, hairy kidney • Differential diagnoses of LCH • BRAF mutation associated with cardiac and neurological phenotype of ECD Haroche J, Papo M #EULAR2023 @RheumNow https://t.co/AzKJKp82nq

What do we do with PMR patients with subclinical GCA seen on ultrasound? Well, in these non-blinded cohorts the subclinical GCA pts got more pred. Was it warranted? Hard to say. If we’re going to look for it, let’s try and figure out what it means POS0712 #EULAR2023 @RheumNow https://t.co/KmCcE0Nsu9

Rx of #lupus #SLE The most challenging seems to be longstanding & residual disease activity - damage accumulates over time - esp if #glucocorticoids are used. Consider only as bridging. How to treat #lupus #EULAR2023 Boumpas ⁦@RheumNow⁩ #ClinicalPearl ⁦@eular_org⁩ https://t.co/heBbcRAjxO

I mean, if proteomics is more your jive for GCA, we’ve got that too here at #EULAR2023. Definite potential for phenotyping a disease with diverse outcomes POS0694 @RheumNow https://t.co/tSWpZlUPoE